PL1773999T3 - Szczepionka do profilaktyki i leczenia zakażenia HIV - Google Patents

Szczepionka do profilaktyki i leczenia zakażenia HIV

Info

Publication number
PL1773999T3
PL1773999T3 PL05769948T PL05769948T PL1773999T3 PL 1773999 T3 PL1773999 T3 PL 1773999T3 PL 05769948 T PL05769948 T PL 05769948T PL 05769948 T PL05769948 T PL 05769948T PL 1773999 T3 PL1773999 T3 PL 1773999T3
Authority
PL
Poland
Prior art keywords
vaccine
hiv
infection
prevention
treatment
Prior art date
Application number
PL05769948T
Other languages
English (en)
Inventor
Helge Abrecht
Martine Delchambre
Martine Marchand
Nathalie Louise Mathy
Philippe Jean Gervais Ghislain Permanne
Gerald Hermann Voss
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of PL1773999T3 publication Critical patent/PL1773999T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL05769948T 2004-08-05 2005-08-03 Szczepionka do profilaktyki i leczenia zakażenia HIV PL1773999T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0417494.2A GB0417494D0 (en) 2004-08-05 2004-08-05 Vaccine
PCT/EP2005/008434 WO2006013106A2 (en) 2004-08-05 2005-08-03 Vaccine for prevention and treatment of hiv-infection
EP05769948A EP1773999B1 (en) 2004-08-05 2005-08-03 Vaccine for prevention and treatment of hiv-infection

Publications (1)

Publication Number Publication Date
PL1773999T3 true PL1773999T3 (pl) 2010-02-26

Family

ID=32982606

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05769948T PL1773999T3 (pl) 2004-08-05 2005-08-03 Szczepionka do profilaktyki i leczenia zakażenia HIV

Country Status (31)

Country Link
US (2) US7612173B2 (pl)
EP (3) EP2130921B1 (pl)
JP (3) JP2008507987A (pl)
KR (1) KR101501495B1 (pl)
CN (2) CN101035897B (pl)
AR (2) AR050102A1 (pl)
AT (1) ATE443769T1 (pl)
AU (1) AU2005268856B2 (pl)
BR (1) BRPI0514108A (pl)
CA (1) CA2575898C (pl)
CY (1) CY1109667T1 (pl)
DE (1) DE602005016810D1 (pl)
DK (1) DK1773999T3 (pl)
ES (3) ES2334044T3 (pl)
GB (1) GB0417494D0 (pl)
HR (1) HRP20090678T1 (pl)
IL (2) IL180947A0 (pl)
MA (1) MA28983B1 (pl)
MX (1) MX2007001515A (pl)
MY (1) MY145614A (pl)
NO (1) NO20070988L (pl)
NZ (1) NZ552976A (pl)
PE (1) PE20060577A1 (pl)
PL (1) PL1773999T3 (pl)
PT (1) PT1773999E (pl)
RU (1) RU2441878C2 (pl)
SG (1) SG155206A1 (pl)
SI (1) SI1773999T1 (pl)
TW (1) TWI365191B (pl)
WO (1) WO2006013106A2 (pl)
ZA (1) ZA200700771B (pl)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020048596A1 (en) * 1994-12-30 2002-04-25 Gregor Cevc Preparation for the transport of an active substance across barriers
WO2000024377A1 (en) * 1998-10-23 2000-05-04 Idea Innovative Dermale Applikationen Gmbh Method for developing, testing and using associates of macromolecules and complex aggregates for improved payload and controllable de/association rates
EP1031347B1 (en) 1999-01-27 2002-04-17 Idea Ag Transnasal transport/immunisation with highly adaptable carriers
EP1031346B1 (en) 1999-01-27 2002-05-02 Idea Ag Noninvasive vaccination through the skin
WO2001001962A1 (en) * 1999-07-05 2001-01-11 Idea Ag. A method for the improvement of transport across adaptable semi-permeable barriers
US7473432B2 (en) * 2002-10-11 2009-01-06 Idea Ag NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery
TW200510425A (en) * 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
CA2584475A1 (en) * 2004-11-12 2006-05-18 Idea Ag Extended surface aggregates in the treatment of skin conditions
BRPI0608798A2 (pt) * 2005-05-12 2011-03-15 Glaxo Group Ltd vetor de adenovìrus, composição imunogênica, uso de um vetor de adenovìrus, método para preparar um vetor, uso de um vetor de vìrus e um carreador ou adjuvante farmaceuticamente aceitável, e, proteìna de fusão
EP2963118B1 (en) 2005-06-01 2017-08-09 California Institute of Technology Method of targeted gene delivery using viral vectors
EP2013227A4 (en) * 2006-05-09 2010-07-28 Jackson H M Found Military Med HIV-1 immunostained compositions
WO2008011636A2 (en) 2006-07-21 2008-01-24 California Institute Of Technology Targeted gene delivery for dendritic cell vaccination
CN103550764A (zh) * 2007-03-02 2014-02-05 葛兰素史密丝克莱恩生物有限公司 疫苗组合物及其在刺激免疫反应中的用途
US9717788B2 (en) 2007-03-02 2017-08-01 Glaxosmithkline Biologicals Sa Method of inducing an immune response against HIV employing HIV immunogens, adenoviral vectors encoding said immunogens, and adjuvant
US20110244496A1 (en) * 2007-03-06 2011-10-06 Rutgers, The State University Hiv reverse transcriptase compositions and methods
EP2142212A2 (en) * 2007-03-26 2010-01-13 International Aids Vaccine Initiative Method of elicting immune response with a modified mva viral hiv-1 vector
CN101678091A (zh) 2007-05-24 2010-03-24 葛兰素史密丝克莱恩生物有限公司 冷冻干燥的抗原组合物
US20100285051A1 (en) * 2007-12-21 2010-11-11 Dominique Ingrid Lemoine Vaccine
WO2010009346A2 (en) 2008-07-16 2010-01-21 Baylor Research Institute Hiv vaccine based on targeting maximized gag and nef to dendritic cells
GB0815872D0 (en) * 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
US8431153B2 (en) 2008-09-09 2013-04-30 Celebrity Biogens, Llc Bioactive composition for the treatment of the HIV/AIDS, method for manufacturing and using the same
EP2456786B2 (en) 2009-07-24 2017-04-19 Immune Design Corp Lentiviral vectors pseudotyped with a sindbis virus envelope glycoprotein
MX2012011189A (es) 2010-03-26 2013-02-07 Glaxosmithkline Biolog Sa Vacuna contra el virus e inmunodeficiencia humana.
US8623375B2 (en) 2010-05-14 2014-01-07 Baxter International Inc. Chimeric OspA genes, proteins, and methods of use thereof
WO2012041842A1 (en) * 2010-09-27 2012-04-05 Glaxosmithkline Biologicals S.A. Vaccine
JP2012120506A (ja) * 2010-12-10 2012-06-28 Tosoh Corp Ａｍｖ逆転写酵素遺伝子、該遺伝子によりコードされるａｍｖ逆転写酵素及び該遺伝子を用いるａｍｖ逆転写酵素の製造方法
GB201022007D0 (en) 2010-12-24 2011-02-02 Imp Innovations Ltd DNA-sensor
JP2013146235A (ja) * 2012-01-20 2013-08-01 Tosoh Corp トリ骨髄芽細胞腫ウイルス逆転写酵素の製造方法
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
US8323662B1 (en) 2012-03-30 2012-12-04 Immune Design Corp. Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein
AU2013237900B2 (en) 2012-03-30 2017-07-27 Immune Design Corp. Lentiviral vector particles having improved transduction efficiency for cells expressing DC- SIGN
US9713635B2 (en) 2012-03-30 2017-07-25 Immune Design Corp. Materials and methods for producing improved lentiviral vector particles
US9782473B2 (en) 2013-03-26 2017-10-10 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human immunodeficiency virus infection
SI3166607T1 (sl) 2014-07-11 2023-01-31 Gilead Sciences, Inc. Modulatorji toličnih receptorjev za zdravljenje HIV-a
KR102014518B1 (ko) 2017-01-05 2019-08-26 서울대학교산학협력단 HIV 1의 p24 단백질을 발현하는 벡터가 도입된 재조합 마이코박테리움 스메그마티스 균주 및 이를 포함하는 백신
GB201812647D0 (en) 2018-08-03 2018-09-19 Chancellor Masters And Scholars Of The Univ Of Oxford Viral vectors and methods for the prevention or treatment of cancer
CN113924114A (zh) 2019-05-22 2022-01-11 吉利德科学公司 Tlr7调节化合物和hiv疫苗的组合
AU2020315598B2 (en) 2019-07-16 2024-12-12 Gilead Sciences, Inc. HIV vaccines and methods of making and using
AU2020384323A1 (en) 2019-11-14 2022-06-02 Aelix Therapeutics, S.L. Dosage regimens for vaccines
WO2021195286A1 (en) 2020-03-27 2021-09-30 Svenska Vaccinfabriken Produktion Ab Compositions and methods for treating and preventing coronaviruses
CA3202466A1 (en) 2021-01-14 2022-07-21 Jiani LI Hiv vaccines and methods of using
TW202330575A (zh) 2021-09-29 2023-08-01 瑞典商斯文斯卡疫苗生產股份有限公司 用於治療及預防冠狀病毒之組成物及方法

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
DE3300234A1 (de) 1983-01-05 1984-07-05 Display-Design GmbH für moderne Verkaufsförderungsmittel und Raumaussstattung, 6233 Kelkheim Etagenturm zur warenausstellung
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
DK643188A (da) * 1987-11-24 1989-05-25 Smithkline Biolog Ekspression af hiv-proteiner i e.coli og s.cerevisiae
US5221610A (en) 1988-05-26 1993-06-22 Institut Pasteur Diagnostic method and composition for early detection of HIV infection
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
JP3723231B2 (ja) 1991-12-23 2005-12-07 ディミナコ アクチェンゲゼルシャフト アジュバント
KR0172970B1 (ko) 1992-06-17 1999-02-01 김영길 Aids백신에 유용한 키메릭 단백 및 그의 제조방법
DE69313134T2 (de) 1992-06-25 1998-02-26 Smithkline Beecham Biolog Adjuvantien enthaltende impfstoffzusammensetzung
KR100310510B1 (ko) 1993-03-23 2002-07-04 장 스테판느 3-0-탈아세틸화모노포스포릴지질a를함유하는백신조성물
US5962635A (en) 1993-05-18 1999-10-05 Biomolecular Research Institute Ltd. Therapeutic compounds
PT729473E (pt) 1993-11-17 2001-02-28 Deutsche Om Arzneimittel Gmbh Dissacaridos de glucosamina metodo para a sua preparacao composicao farmaceutica contendo os mesmos e sua utilizacao
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
AU713040B2 (en) 1994-07-15 1999-11-18 University Of Iowa Research Foundation, The Immunomodulatory oligonucleotides
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
GB9620795D0 (en) 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6083716A (en) 1996-09-06 2000-07-04 The Trustees Of The University Of Pennsylvania Chimpanzee adenovirus vectors
WO1998016247A1 (en) 1996-10-11 1998-04-23 The Regents Of The University Of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
AU734180B2 (en) 1997-08-29 2001-06-07 Antigenics Llc Compositions comprising the adjuvant qs-21 and polysorbate or cyclodextrin as excipient
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
EP1279401B1 (en) 1997-09-05 2008-01-09 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
GB9720585D0 (en) 1997-09-26 1997-11-26 Smithkline Beecham Biolog Vaccine
ATE435034T1 (de) 1998-08-04 2009-07-15 Jackson H M Found Military Med Expression und charakterisierung eines hiv-1 hüllproteins, das mit einer breitreaktiven neutralisierenden antikörperantwort assoziiert ist.
AU782193B2 (en) 1999-12-17 2005-07-07 Merck & Co., Inc. Polynucleotide vaccines expressing codon optimized HIV-1 Nef and modified HIV-1 Nef
DK1240186T3 (da) * 1999-12-23 2010-05-31 Medical Res Council Forbedringer i eller relateret til immunrespons mod HIV
US20020155127A1 (en) * 2000-06-02 2002-10-24 Danher Wang Genetic vaccine against human immunodeficiency virus
JP2004508064A (ja) 2000-09-15 2004-03-18 メルク　エンド　カムパニー　インコーポレーテッド コドン最適化ｈｉｖ１−ｇａｇ、ｐｏｌ、ｎｅｆおよび修飾体を発現する増強された第１世代アデノウイルスワクチン
CU23235A1 (es) 2001-02-28 2007-09-26 Ct Ingenieria Genetica Biotech POXVIRUS RECOMBINANTES PARA PROTEINAS QUIMéRICAS DEL VIRUS DE LA INMUNODEFICIENCIA HUMANA Y SU APLICACION EN LA TERAPéUTICA Y LA PREVENCION DEL SIDA
AU2002327338A1 (en) * 2001-07-25 2003-02-17 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer
JP4601956B2 (ja) * 2001-09-20 2010-12-22 グラクソ グループ リミテッド Ｈｉｖ−ｇａｇのコドン最適化ｄｎａワクチン
MXPA04004876A (es) 2001-11-21 2004-07-30 Univ Pennsylvania Secuencias de acido nucleico y de aminoacido de adenovirus de simio, vectores que contienen los mismos y metodos de uso.
US20030134404A1 (en) 2001-11-26 2003-07-17 Lochrie Michael A. Methods for producing stocks of recombinant AAV virions
US20050266024A1 (en) * 2002-03-19 2005-12-01 Powdermed Limited Adjuvant
US20030190308A1 (en) * 2002-03-19 2003-10-09 Braun Ralph P. Adjuvant
RU2004135541A (ru) * 2002-06-11 2005-10-10 ГлаксоСмитКлайн Байолоджикалз с.а. (BE) Иммуногенные композиции
GB0225788D0 (en) * 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
GB0225786D0 (en) * 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
US7501503B2 (en) * 2002-12-31 2009-03-10 Mcgill University Compositions and methods for inhibiting RNase H activity of retroid reverse transcriptase
US20050175627A1 (en) 2003-09-24 2005-08-11 Oxxon Therapeutics Ltd. HIV pharmaccines
AU2004276559A1 (en) 2003-09-24 2005-04-07 Oxxon Therapeutics Limited HIV pharmaccines

Also Published As

Publication number Publication date
CN102633866B (zh) 2015-04-15
EP2280073A3 (en) 2011-06-29
EP1773999A2 (en) 2007-04-18
ES2445453T3 (es) 2014-03-03
CY1109667T1 (el) 2014-08-13
ZA200700771B (en) 2009-04-29
CA2575898C (en) 2015-09-29
US20100184836A1 (en) 2010-07-22
EP2130921B1 (en) 2013-11-20
AU2005268856B2 (en) 2012-05-24
GB0417494D0 (en) 2004-09-08
KR20070041765A (ko) 2007-04-19
BRPI0514108A (pt) 2008-05-27
IL180947A0 (en) 2007-07-04
RU2007104088A (ru) 2008-09-10
ES2486669T3 (es) 2014-08-19
MX2007001515A (es) 2007-09-07
DK1773999T3 (da) 2010-01-18
MA28983B1 (fr) 2007-11-01
ES2334044T3 (es) 2010-03-04
AR080216A2 (es) 2012-03-21
WO2006013106A2 (en) 2006-02-09
AU2005268856A1 (en) 2006-02-09
JP2011234722A (ja) 2011-11-24
CN101035897B (zh) 2012-02-01
KR101501495B1 (ko) 2015-03-11
SG155206A1 (en) 2009-09-30
NZ552976A (en) 2010-01-29
US20070243203A1 (en) 2007-10-18
NO20070988L (no) 2007-05-04
HK1108168A1 (en) 2008-05-02
ATE443769T1 (de) 2009-10-15
CN102633866A (zh) 2012-08-15
JP5629647B2 (ja) 2014-11-26
JP6007212B2 (ja) 2016-10-12
EP1773999B1 (en) 2009-09-23
RU2441878C2 (ru) 2012-02-10
WO2006013106A3 (en) 2006-08-17
IL207575A0 (en) 2011-07-31
AR050102A1 (es) 2006-09-27
PE20060577A1 (es) 2006-08-07
PT1773999E (pt) 2009-12-16
EP2280073B1 (en) 2014-06-11
DE602005016810D1 (de) 2009-11-05
EP2130921A3 (en) 2010-03-03
MY145614A (en) 2012-03-15
JP2008507987A (ja) 2008-03-21
JP2014239687A (ja) 2014-12-25
HRP20090678T1 (hr) 2010-01-31
TW200621806A (en) 2006-07-01
EP2130921A2 (en) 2009-12-09
EP2280073A2 (en) 2011-02-02
SI1773999T1 (sl) 2010-01-29
CA2575898A1 (en) 2006-02-09
CN101035897A (zh) 2007-09-12
TWI365191B (en) 2012-06-01
US7612173B2 (en) 2009-11-03

Similar Documents

Publication Publication Date Title
ZA200700771B (en) Vaccine for prevention and treatment of HIV-infection
HRP20190008T1 (hr) Prevencija i liječenje sinukleinopatske i amiloidogene bolesti
AU2003290548A8 (en) Prevention and treatment of synucleinopathic disease
IL177914A0 (en) Use of indazolecarboxamide derivatives for the preparation of a medicament that is intended for the treatment and prevention of paludism
IL181896A0 (en) Methods and compositions for the treatment of hyperlipidemia
ZA200803493B (en) Methods and pharmaceutical compositions for the treatment and prevention of hepatitis C infection
ZA200709727B (en) Compounds and methods for the treatment of prevention of flavivirus infections
EP1618185A4 (en) NEW IMMUNOLOGICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF MENINGOCOCCOULAR DISEASE
IL182436A0 (en) Thienopyridinone compounds and methods of treatment
IL178996A0 (en) Thienopyridinone compounds and methods of treatment
GB0610350D0 (en) prevention and/or treatment of neuodegenerative disorders
IL187405A0 (en) Methods and compositions for the treatment of pain
ZA200701531B (en) Prevention and treatment of synucleinopathic and amyloidogenic disease
ZA200703087B (en) Methods and compositions for the treatment of hyperlipidemia
EP1814567A4 (en) USE OF MODULATORS OF EPHA2 AND EPHRINA1 FOR TREATING AND PREVENTING INFECTIONS
GB2441094B (en) Methods for treatment and prevention of infection
PL1812797T3 (pl) Kompozycje i sposoby do leczenia chorób hiperproliferacyjnych i zapobiegania tym chorobom
GB201010682D0 (en) Methods for treatment and prevention of infection
GB0510257D0 (en) Methods for treatment and prevention of infection
ZA200710476B (en) Methods and compositions for the treatment of pain
GB0612749D0 (en) Treatment and/or prevention of pain
GB0313065D0 (en) Vaccine and therapeutic treatment
EP1928473A4 (en) COMBINATION OF POLYCHITOSAMINE AND FIBRATE FOR THE PREVENTION AND TREATMENT OF HYPERLIPIDEMIA
KR100531650B1 (ko) 아프리카산 상황버섯 추출물을 함유하는 감기의 치료 및예방을 위한 약학조성물
GB0414428D0 (en) Compounds and methods of treatment